NCT02477631 - Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

June 30, 2018

Conditions

Myelodysplastic Syndrome With Low-grade LesionsIron Overload Due to Repeated Red Blood Cell Transfusions

Interventions

DRUG

Deferiprone

This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.

Trial Locations (1)

Chim Sheba Medical Center, Tel Litwinsky